Gleevec and Bilirubin conjugated increased - a phase IV clinical study of FDA data

Summary:

Bilirubin conjugated increased is reported as a side effect among people who take Gleevec (imatinib mesylate), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Omeprazole, and have Gastrointestinal stromal tumor.

The phase IV clinical study analyzes which people have Bilirubin conjugated increased when taking Gleevec. It is created by eHealthMe based on reports of 35,000 people who have side effects when taking Gleevec from the FDA, and is updated regularly.

What is Gleevec?

Gleevec has active ingredients of imatinib mesylate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 35,415 Gleevec users. Check the latest studies of Gleevec.

What is Bilirubin conjugated increased?

Bilirubin conjugated increased is found to be associated with 429 drugs and 684 conditions by eHealthMe. Check the latest studies of Bilirubin conjugated increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

35,000 people reported to have side effects when taking Gleevec.
Among them, 16 people (0.05%) have Bilirubin conjugated increased.

Could Gleevec cause Bilirubin conjugated increased?

Among these 16 people:

How long have people been on Gleevec when they have Bilirubin conjugated increased? *

What is the gender of people who have Bilirubin conjugated increased when taking Gleevec? *

female: 62.5 %
male: 37.5 %

What is the age of people who have Bilirubin conjugated increased when taking Gleevec? *

What are other drugs people take besides Gleevec? *

What are other side effects people have besides Bilirubin conjugated increased? *

Alanine Aminotransferase Increased: 13 people, 81.25%
Aspartate Aminotransferase Increased: 12 people, 75.00%
Blood Alkaline Phosphatase Increased: 12 people, 75.00%
Blood Bilirubin Increased: 11 people, 68.75%
Nausea (feeling of having an urge to vomit): 7 people, 43.75%
Gamma-Glutamyltransferase Increased: 6 people, 37.50%
Diarrhea: 5 people, 31.25%
Thrombocytopenia (decrease of platelets in blood): 5 people, 31.25%
Blood Bilirubin Unconjugated Increased: 5 people, 31.25%
Serum Ferritin Increased: 4 people, 25.00%

What are the existing conditions these people have? *

Irritable Bowel Syndrome: 3 people, 18.75%
Gastrointestinal Stromal Tumor: 3 people, 18.75%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 2 people, 12.50%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 1 person, 6.25%
Insomnia (sleeplessness): 1 person, 6.25%
Depression: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Gleevec and have Bilirubin conjugated increased?

- Check whether Bilirubin conjugated increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gleevec:

Gleevec (35,415 reports)

Browse all side effects of Gleevec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bilirubin conjugated increased:

Bilirubin conjugated increased (429 drugs)

Browse all the conditions that are associated with Bilirubin conjugated increased:

Bilirubin conjugated increased (684 conditions)

Related publications that referenced our studies

O'rafferty C, McElligott F, Storey L, O'marcaigh A, Smith O, "Pneumatosis intestinalis and imatinib mesylate", Annals of hematology, 2014 Oct .
O'rafferty C, McElligott F, Storey L, O'marcaigh A, Smith O, "Pneumatosis intestinalis and imatinib mesylate", Annals of hematology, 2014 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on imatinib mesylate (the active ingredients of Gleevec) and Gleevec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.